SP
Publicaties op Oncologisch.com
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, r...
Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.
A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with ...
CLL-therapie gestuurd door MRD: overzicht
Ibrutinib-rituximab versus FCR bij eerder onbehandelde CLL: E1912 vijfjaars definitief